checkAd

     177  0 Kommentare Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia - Seite 4

    Contact: 
    Kim Fox, Vice President, Communications, kfox@milestonepharma.com 

    Investor Relations 
    Chris Calabrese, ccalabrese@lifesciadvisors.com 
    Kevin Gardner, kgardner@lifesciadvisors.com 



    globenewswire
    0 Follower
    Autor folgen
    Seite 4 von 4

    Verfasst von globenewswire
    Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia - Seite 4 MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) - Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the …

    Schreibe Deinen Kommentar

    Disclaimer